The singer shared an emotional update about her twins’ health on Sunday and that ‘time is of the essence with this disease’ ...

Former Little Mix star Jesy Nelson revealed on social media that her twin girls have been diagnosed with a rare genetic ...

Spinal muscular atrophy (SMA) is a genetic neuromuscular disease affecting specialized nerve cells that control voluntary muscle movement, according to the Muscular Dystrophy Association (MDA). It can ...

Spinal muscular atrophy (SMA) and spina bifida are distinct conditions that affect the nerves that allow for voluntary motor control. Share on Pinterest press coverage photography/Getty Images SMA is ...

An expert neurologist, Emma Ciafaloni, MD, provides an overview of the epidemiology of spinal muscular atrophy and discusses symptom burden, differential diagnosis, and prevalence. Dennis Scanlon, PhD ...

Dennis P. Scanlon, PhD; Emma Ciafaloni, MD; Maria Lopes, MD, MS; Kevin U. Stephens, Sr, JD, MD; and Mary Schroth, MD, FAAP, FCCP provide an overview of the disease burden in spinal muscular atrophy ...

Evrysdi can stabilize motor function, improve swallowing ability, ease fatigue, and improve life quality for adults with SMA, ...

There’s no cure for spinal muscular atrophy (SMA). But there are treatments. Three medications can help slow down SMA symptoms. In some cases, they may be able to stop the disease from getting worse.

DelveInsight's “Spinal Muscular Atrophy Pipeline Insight 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in the Spinal Muscular Atrophy pipeline landscape. It ...

Injections for spinal muscular atrophy (SMA) refer to two treatments that the Food and Drug Administration (FDA) has approved for SMA: nusinersen (Spinraza) and onasemnogene abeparovec-xioi (Zolgensma ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

(MENAFN- GlobeNewsWire - Nasdaq) Opportunities in the SMA market include leveraging the launch of new myostatin inhibitors, expanding Zolgensma formulations to increase patient eligibility, and ...